NEYGenomics

Struggling to know where to start with #genomics? Try this 30-minute course providing a strong foundational of knowledge, regardless of your profession or specialty: https://buff.ly/3yxv30E #Genomics101 #GenomicsInHealthcare

If you're a nursing educator looking to #teach #genomics to a pre-reg class, then our toolkit will help set you up for success! Endorsed by the Royal College of Nursing, you can access the material here: https://buff.ly/44j9njX

Our clinical director, Professor Kate Tatton-Brown, provides an insight into how genomic technologies have developed and why education and training in their use is so important. https://buff.ly/3M0hp9q

What is a #bioinformatician? And how do they harness #bigdata to improve patient care? Find out more about this vital role in our genomics careers series: https://buff.ly/4cfvvhQ

Trying to find the genomic variant responsible for disease is like trying to find the one, correct ball in a huge ball pit. Clinicians, find out the vital part you play when ordering a genomic test that will help maximise the chances. https://buff.ly/4egrcow #genomics

We’re so proud to see the lung circulating tumour DNA project being recognised by the #HSJAwards as a shortlisted entrant in the Modernising Diagnostics category. This NHS England commissioned pilot study aims to evaluate how liquid biopsy testing can be brought into an established NHS lung cancer diagnostic pathway. Liquid biopsy tests, also known as circulating tumour DNA (ctDNA) tests, sequence fragments of tumour DNA that are released into the blood stream. While this type of genetic testing is an established technology, currently no national healthcare services offer ctDNA in mainstream testing, making this a world first. Over 2000 patients accessed the test during the early stages of the pilot, this has now been expanded to offer a further 10,000 tests in 2024/25. Bringing new genomic tests to patients across the NHS is only possible thanks to collaborations with other regional partners as well as industry! We are proud to have led the delivery of this pilot alongside the NEYGenomics - working with teams from Roche and Guardant Health who developed the technology and have been instrumental in working with the NHS to help deliver the testing. These partnerships have ultimately led to the NHS being able to bring testing in-house to our lab at The Royal Marsden NHS Foundation Trust and eventually to Manchester from the NHS North West Genomic Medicine Service Alliance in the near future to build capacity. Additionally, working with the wonderful team at Edge Health UK to produce a health economic analysis of the impact of implementing ctDNA testing in the lung cancer pathway to assess if commissioning the test would have long-term economic benefit to the NHS. It is fantastic to see the benefits of these tests across England - ensuring patients have faster access to precision treatment. We are excited to continue working, through this collaboration between the NHS and industry, in the next phase of the pilot and beyond. Read more about the first phase of this pilot 👇 https://lnkd.in/emRJeduh